Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

Phase 2 Trial: Tofacitinib Lowers Interferon Activity in Down Syndrome

A CU Anschutz open-label phase 2 trial of tofacitinib in Down syndrome met its safety endpoint and lowered interferon markers; benefit is exploratory.

Published 19 Nov 2026· 6 minute read
The University of Colorado Anschutz Medical Campus in Aurora, Colorado, seen at dawn
Photo: Nolabob / Wikimedia Commons, CC BY-SA 4.0 (cropped). Source · Licence

On 17 and 18 November 2026, researchers at the University of Colorado Anschutz reported in Cell Reports Medicine the results of a phase 2, open-label, single-arm trial of the JAK inhibitor tofacitinib in people with Down syndrome and inflammatory skin conditions. The trial met its safety endpoint and lowered blood markers of interferon activity, but with no placebo group, the authors call the clinical benefits exploratory.

What happened

The paper, titled “A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome,” was published online on 17 November 2026 in Cell Reports Medicine (DOI 10.1016/j.xcrm.2026.103138), and CU Anschutz announced it on 18 November through the Linda Crnic Institute for Down Syndrome. The senior author is Joaquín Espinosa, executive director of the Crnic Institute, and the first author is Angela Rachubinski.

The authors start from the observation that Down syndrome is marked by strong immune dysregulation and hyperactive interferon/JAK/STAT signalling. Tofacitinib blocks JAK1 and JAK3, enzymes that relay signals from interferon and other cytokines inside immune cells, so the team tested whether it would dampen that signalling. According to the abstract, tofacitinib decreased interferon scores, cytokine scores and neurotoxic immunometabolites without overt immune suppression, and participants benefited in immune-mediated skin conditions, most prominently hidradenitis suppurativa and alopecia areata.

The abstract also reports improvements on several neuropsychological assessments, and the authors state plainly that without a placebo control arm, efficacy findings remain exploratory.

Key details of the trial

Item What the record shows
Study type and phase Phase 2, interventional, single-group, open-label (no masking, no placebo group)
Registration ClinicalTrials.gov NCT04246372, “Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome”
Participants Adolescents and adults with Down syndrome and immune skin conditions; the registry lists ages 12 to 50 (weight of at least 40 kg) and an actual enrolment of 47
Treatment period 16 weeks, with an optional extension to 40 weeks (the paper’s abstract says up to nine months)
Registered primary outcomes Number of serious adverse events definitely related to tofacitinib; change in the whole-blood transcriptome interferon score from baseline to 16 weeks
Dates Started 21 October 2020; primary and study completion 30 October 2024 (registry, actual)
Sponsor and funding Sponsor: University of Colorado, Denver; registry collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The university release names the NIH INCLUDE Project, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation and the Ruth E. Olleman Trust as funders

The measured results are mostly reported as findings rather than headline percentages. The trial met its predefined primary safety endpoint, with a safety profile the authors describe as similar to that seen in the general population. Blood analyses showed significant reductions in interferon activity, in inflammatory cytokine scores and in inflammation-linked metabolites including quinolinic acid, which has known neurotoxic effects. Skin outcomes were assessed with standardised clinical scores and dermatology-related quality-of-life measures. Neuropsychological testing covered attention, memory, vocabulary and behaviour, alongside participant- and caregiver-reported changes.

Background and context

This is the full report of a trial the same group first described in interim form in 2024. In August 2024, Medical Xpress covered an eLife reviewed preprint on the first participants, which reported improvements in skin pathology, most strikingly in alopecia areata, and said inflammatory markers elevated in Down syndrome returned toward the normal range. At that point the authors said more data were needed to define the safety profile of JAK inhibitors in Down syndrome, and that most participants had chosen to stay on the medicine after the trial, often through off-label prescriptions. The 2026 paper reports treatment for up to nine months, multi-omics analyses of the pathways tofacitinib modulates, and the neuropsychological assessments.

Tofacitinib is an existing drug, so the trial is a repurposing study: the question is whether a medicine already used for other immune-mediated conditions is safe and active in a group whose immune system is chronically activated. That is why the registered primary outcomes pair a safety count with a molecular measure, the interferon score, rather than a skin or cognitive score alone. For readers new to the vocabulary, a phase 2 trial is typically the stage that gathers early evidence of activity and further safety data in a limited group, and the registry entry follows the clinical trial registration norms that let readers compare what was planned with what was reported.

Reaction and what the authors say

Espinosa said in the university release: “We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions.” The release also quotes Rachubinski as saying the medication appears to calm an overactive immune system while preserving normal immune defences, with several abnormal inflammatory markers moving closer to the levels observed in people without Down syndrome.

The release is equally direct about limits. Lina Patel, a coauthor and professor of psychiatry at CU Anschutz, said: “The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition.” Because every participant received the drug, practice effects and other factors cannot be separated from a treatment effect. The authors also say that the safety result does not remove the known risks of JAK inhibitors and that long-term safety needs larger studies.

What it means for researchers, universities and research offices

Reading the evidence. This is a single-arm study. The skin, biomarker and neuropsychological outcomes are exploratory, and the two registered primary outcomes are the ones the design was built to test. Investigators planning follow-on work should note that the authors point to randomised, placebo-controlled trials to assess clinical benefit, participant selection and longer-term safety; a placebo-controlled design is the step that would let practice effects be separated from drug effects in the cognitive measures.

Regulatory status. Tofacitinib is not approved for Down syndrome, and the authors state that the study does not establish a general treatment recommendation. Research offices and clinical trials units should treat this as an early-phase finding. Any institutional communication about it should repeat that status and avoid language suggesting an available therapy.

Funding and registration. The trial combines federal and philanthropic support, including the NIH INCLUDE Project, with NIAMS listed as the registry collaborator. The registry entry on ClinicalTrials.gov carries the registered primary outcomes, so sponsors and reviewers can check them against the paper. Safety reporting in such studies depends on definitions such as serious adverse events, which is the unit of the first registered primary outcome.

Data reuse. The Crnic Institute plans to link the findings to its Human Trisome Project data to identify responsive biological changes and monitoring biomarkers, a reminder that molecular endpoints collected in a small trial gain value when they can be compared with a larger observational cohort.

What happens next

According to the release, the next steps are randomised, placebo-controlled trials to assess clinical benefit, who is most likely to respond, and longer-term safety. A second trial, on Down Syndrome Regression Disorder, a condition involving sudden loss of neurological function, has launched, with results expected in 2027. Further analysis will link the trial’s biomarker data with Human Trisome Project data to identify responsive biological changes and monitoring biomarkers.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →